+6 year(s) experience
Tara is proudest of her work covering the Zika virus, which involved producing a report on the landscape of the vaccine, treatment, and diagnostic development for the disease.
Before joining Informa in 2015, she worked for medical device company Hologic, gaining insight into the development of medical devices and GMP regulations.
Datamonitor Healthcare, Pink Sheet
The FDA Oncology Center of Excellence’s ‘industry-wide evaluation’ of accelerated approvals has already led to withdrawals of four PD-1/PD-L1 inhibitor indications, with the Oncologic Drugs Advisory Committee set to review another six in late April. Over the next two years, an additional five indications may be up for review.